PHARVARIS NV
1 day chart
Kickstart your portfolio with a U.S. stock on us
Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.
Sign up and fund a new Wall St account and get a full U.S. share.
T&Cs apply
About PHVS
Pharvaris NV is a Netherlands-based company primarily engaged in the biopharmaceutical industry. The Company focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. It is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The Company is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.
Find out what a historical investment in PHARVARIS NV would be worth today using our PHVS stock calculator.
$907.60M
-
0.00%
11.26K
$16.96
$16.31
$16.84
$25.50
$11.51
Ready to start your investing journey with Stake?
Open an accountPHVS FAQs
- Sign up with some I.D. and zero paperwork
- Add funds to your account
- Make your first investment in PHVS
This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.
Invest in PHVS
on Stake
Buy PHVS from US$3 brokerage
Invest in 9,500+ U.S. stocks and ETFs
Own a slice of PHVS from only US$10 with fractional shares
